Fortrea Holdings Inc. (FTRE) Stock
FTRE has an Alpha Score of 35 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 1 trade in FTRE since 2025: 0 purchases and 1 sale, most recently James French Hill (sale, Jun 23, 2025). 5 of the hedge funds AlphaScala tracks reported FTRE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $22.44M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is FTRE's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with strong momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Fortrea Holdings Inc. (FTRE)?
Most recent: James French Hill (sale, Jun 23, 2025); records start Jun 23, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| French Hill R-AR · House | 2025-06-23 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all FTRE political trades →Which hedge funds own FTRE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.29M | $22.44M | -10% |
| Citadel Ken Griffin | 1.02M | $17.80M | +101% |
| Millennium Management Israel Englander | 626K | $10.90M | +148% |
| D.E. Shaw David Shaw | 127K | $2.21M | +140% |
| Marshall Wace | 83K | $1.44M | -72% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Fortrea Holdings Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 9, 26 | Morais Mark A. | Chief Operating Officer | SELL | 3.1K | $53K |
| Sep 9, 26 | Russell Carrie Elizabeth | Interim CAO | SELL | 246 | $4K |
| Aug 19, 26 | Morais Mark A. | Chief Operating Officer | SELL | 4.9K | $89K |
| Aug 6, 26 | Thakral Anshul | Chief Executive Officer | SELL | 55.9K | $1.0M |
| Aug 6, 26 | Thakral Anshul | Chief Executive Officer | SELL | 56.0K | $1.0M |
| Aug 5, 26 | Thakral Anshul | Chief Executive Officer | SELL | 49.5K | $941K |
| Aug 5, 26 | Thakral Anshul | Chief Executive Officer | SELL | 50.4K | $972K |
| Aug 3, 26 | Sanders Machelle | Director | SELL | 9.7K | $175K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are FTRE's key statistics?
Key statistics as of Nov 9, 2026
How does FTRE's valuation compare with the Healthcare sector?
| Metric | FTRE | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -2.58% | 3.66% | 170 |
| Return on equity | -12.81% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
FTRE price chart
Powered by TradingViewWhat does Fortrea Holdings Inc. do?
Fortrea Holdings Inc. is a global contract research organization (CRO) providing comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide. It specializes in Phase I through IV clinical trial management, clinical pharmacology, pharmacovigilance, regulatory affairs, data management, biostatistics, and consulting services across more than 20 therapeutic areas, including oncology, central nervous system disorders, rare diseases, and cell and gene therapies. The company operates through Clinical Services and Enabling Services segments, offering flexible delivery models such as full-service, functional service provider, and hybrid structures to streamline trial processes, optimize drug supply, and support patient dosing. Fortrea Holdings Inc. emphasizes innovation in decentralized trials, site partnerships, and technology integration to accelerate development timelines and enhance operational efficiency. Incorporated in 2023 and headquartered in Durham, North Carolina, it conducts operations in approximately 90 countries, partnering with sponsors to advance healthcare innovations from early-phase studies to post-approval support.